Trial Profile
Study on Biomarkers Using Circulating Tumor Cells When Administering Osimertinib in Patients with EGFR Mutation-positive Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms CTC-BIOME
- 01 Apr 2021 Status changed from not yet recruiting to completed.
- 04 Apr 2018 New trial record